Navigation Links
Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal

et.news.net">www.asianet.news.net


    ENQUIRIES:

    Dr Pete Smith

    Alchemia Limited Chief Executive Officer

    Tel: +61-7-3340-0200


    RELEASED BY:

    Mr Geoff Breusch

    Phillips Group

    Tel: +61-7-3230-5000
 

About HyACT(TM)

HyACT(TM) is a proprietary technology which utilises hyaluronic acid (HA), to deliver and enhance the retention of anti-cancer drugs and biologics within tumours. The drug becomes entrained within the HA matrix and the HA binds to receptors located on the tumour cell resulting in more of the drug being delivered to the tumour. Preclinically, the HyACT(TM) technology has demonstrated improved delivery of drug to the tumour resulting in significantly reduced toxicity as well as increased efficacy and survival.

About Camptosar(R) (irinotecan)

Camptosar(R) is widely used in the treatment of metastatic colorectal cancer, and is being evaluated in many other tumour types. Like most cytotoxic drugs the use of Camptosar(R) is restricted by its side-effects, the most significant of which are diarrhea and neutropenia. Sales of Pfizer's Camptosar(R) were US$903 million in 2006. Patent exclusivity for the drug expires in 2008 in the US and 2009 in the EU.

Camptosar(R) is a registered trade mark of Pfizer Inc.

About HyCAMP(TM)

HyCAMP(TM) is a proprietary formulation of the anti-cancer drug Camptosar(R) with HA. Preclinical studies with HyCAMP(TM) demonstrated improved delivery of the drug to the tumour, resulting in increased efficacy and reduced toxicity. The phase II clinical trial was initiated to evaluate HyCAMP(TM) in patients with metastatic colorectal cancer.

HyACT(TM) and HyCAMP(TM) were obtained through Alchemia's acquisition of Melbourne-based oncology company Meditech Research Ltd in 2006.

This clinical study was financially supported in part by NovoZymes Biopolymer A/S.

CONTACT: Dr Pete Smith, Chief Executive Officer of Alchemia Limited,+61
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Positive Final Data from HyCAMP Phase Trial Metastatic Colorectal
(Date:7/30/2015)... Japan , July 30, 2015 ... of the study to fulfill the post-marketing commitment ... the Pan European Multi-Database Bladder Cancer Risk ... retrospective matched cohort study, conducted in four European ... HCI) with up to 10 years of follow-up. ...
(Date:7/30/2015)... 30, 2015 Global ENT ... to reach USD 23.01 million in 2022, according to ... base of geriatric population, increasing prevalence of ear, nose, ... of awareness among target customer base are expected serve ... forecast period. According to estimates published by the WHO, ...
(Date:7/30/2015)... LONDON , July 30, 2015 ... devices market ? Which areas are going to grow ... report shows you potential revenues to 2025, assessing data, ... report provides 176 tables, charts, and graphs. ... the future market prospects. Our new study lets you ...
Breaking Medicine Technology:Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
... BEIJING, Dec. 31, 2010 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. ... the "Company"), a fast-growing, profitable developer, manufacturer and seller ... China ("PRC"), announced today that the Company will effect ... order to meet minimum share price requirements in connection ...
... WOONSOCKET, R.I., Dec. 31, 2010 CVS Caremark (NYSE: ... into an agreement to acquire the Medicare Part D ... for approximately $1.25 billion.  Universal American is a leading ... New York. The acquisition will more than double the ...
Cached Medicine Technology:Lotus Pharmaceuticals Announces Approval of Reverse Stock Split 2CVS CAREMARK to Purchase Universal American's Medicare Part D Business 2CVS CAREMARK to Purchase Universal American's Medicare Part D Business 3CVS CAREMARK to Purchase Universal American's Medicare Part D Business 4
(Date:7/31/2015)... ... July 31, 2015 , ... BioViva USA, Inc. (“BioViva”), a ... treat aging diseases. , BioViva announces it has begun a fundraiser through Maximum ... Disease (AD) and find a cure. MaxLife will grant 100% of the money raised ...
(Date:7/31/2015)... ME (PRWEB) , ... July 31, 2015 , ... The alarm was ringing. Hugh Chatfield, ... Glancing out of the window, he recalled that his equipment was set up to depict ... tower, he jumped out of bed. , The photo speaks for itself. Chatfield is also ...
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... Awarded ... Hair Restoration is proud to announce that they are the latest recipients of the ... cements their status as one of the worldwide leaders in the science of hair ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... selected as a contributor for LeadingAge’s Center for Aging Services Technologies (CAST) Medication ... to help long-term and post-acute care providers understand the benefits of using ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... Emergency Medicine Practice, and Hospital Medicine Practice, is pleased to announce that it ... a mobile application format available on iPhones, iPads, and Android smartphones and tablets. ...
Breaking Medicine News(10 mins):Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3
... 6 May 2010 -- Researchers from Cold Spring Harbor Laboratory ... analyzing the genome of single tumor cells. The breakthrough allows ... tumors develop and has the potential to help doctors identify ... from the prostate or a non-invasive lesion in the breast. ...
... May 2010 -- A new study of metastatic breast ... patients have in their blood directly correlates with the ... Cancer Conference in Brussels, Belgium, the results have the ... these patients. Circulating tumor cells --cancer cells found ...
... After menopause, 6 to 10 million women take hormone ... progestin, to replace hormones lost from inactive ovaries. Progestin ... potentially negative effects of estrogen therapy on the uterus. ... evidence has been found that estrogen and progestin in ...
... ... , ... (PRWEB) May 6, 2010 -- CosmoCom the global leader in Contact Center Consolidation ... prestigious 2010 Long Island Software Award (LISA). Presented by the Long Island Software and ...
... ... steady employment in a highly competitive market. In order to gain a competitive edge against ... appearance. Non-surgical med spa treatments can offer many benefits during a job hunt. , ... (PRWEB) May 6, 2010 -- With ...
... ... achieving top performance from GPUs in diverse applications using Monte Carlo simulations can now ... Group (NAG). , ... (Vocus) May 6, 2010 -- Developers and researchers who are interested in achieving top ...
Cached Medicine News:Health News:Genome breakthrough allows scientists to identify and profile tumor cells from very small samples 2Health News:Survival in metastatic breast cancer directly linked to circulating tumor cells 2Health News:Breast cancer metastasis increases after estrogen and progestin hormone therapies, MU study finds 2Health News:CosmoCom Wins Software Award for CosmoHealth 2Health News:CosmoCom Wins Software Award for CosmoHealth 3Health News:Med Spa Treatments Become More Popular as Unemployment Rates Climb 2Health News:Med Spa Treatments Become More Popular as Unemployment Rates Climb 3Health News:More GPU Routines for Technical Research Now Available from Numerical Algorithms Group 2Health News:More GPU Routines for Technical Research Now Available from Numerical Algorithms Group 3
The ImagingPlanet 55 mm surgical microscope video adapter: superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Leica surgical ...
The ImagingPlanet 55 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Zeiss surgical micro...
Introducing Optronics DVMR, the first digital surgical documentation system designed for the microsurgical operating room environment. DVMR accepts images from a variety of high-resolution cameras fo...
Research Grade Microscope Camera from ImagingPlanet Research Microscopy Group, a superior imaging technology that delivers increased image resolution and precise color accuracy at an affordable pric...
Medicine Products: